PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
March 13, 2024Nature CommunicationsOpen Access

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChang‐Ching LinTCTsung-Cheng ChangYWYunguan Wang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lin et al. (2024) studied this question.

synapsesocial.com/papers/68e74210b6db6435876bbf28https://doi.org/10.1038/s41467-024-46495-2
View Full Paper
Ask AI
Bookmark
Share